Analysts Offer Insights on Healthcare Companies: Personalis (PSNL), Waters (WAT) and Alkermes (ALKS)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Personalis (PSNL – Research Report), Waters (WAT – Research Report) and Alkermes (ALKS – Research Report) with bullish sentiments.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Personalis (PSNL)
In a report released today, William Bonello from Craig-Hallum maintained a Buy rating on Personalis. The company’s shares closed last Monday at $7.83.
According to TipRanks.com, Bonello is a 5-star analyst with an average return of
Personalis has an analyst consensus of Strong Buy, with a price target consensus of $11.33, representing a 41.4% upside. In a report issued on January 26, Guggenheim also maintained a Buy rating on the stock with a $13.00 price target.
See the top stocks recommended by analysts >>
Waters (WAT)
In a report released today, Tycho Peterson from Jefferies maintained a Buy rating on Waters, with a price target of $470.00. The company’s shares closed last Monday at $328.14.
According to TipRanks.com, Peterson is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Waters with a $418.09 average price target, representing a 25.8% upside. In a report issued on January 27, HSBC also initiated coverage with a Buy rating on the stock with a $460.00 price target.
Alkermes (ALKS)
Jefferies analyst Akash Tewari maintained a Buy rating on Alkermes today and set a price target of $58.00. The company’s shares closed last Monday at $34.84, close to its 52-week high of $36.45.
According to TipRanks.com, Tewari is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alkermes with a $46.20 average price target, representing a 33.4% upside. In a report issued on January 27, TipRanks – OpenAI also reiterated a Buy rating on the stock with a $38.00 price target.
